Future studies should incorporate longitudinal data to validate the increased levels of GALE, MYOC, AMBP, and DPT in MFS patients as potential indicators of early‐stage disease and also to explore new biomarkers for other ocular system syndromes. This evidence concerns the gene AMBP and Marfan syndrome.